Clinical Trial Update: VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV [Phase 3]

View source ↗

Summary

Phase 3 trial update for VA-006 Vaccinia Vaccine (ACAM2000) assessing production of VIGIV; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox Vaccine Adverse Reaction

Drugs mentioned

• VA-006 Vaccinia Vaccine (ACAM2000) (ACAM2000)

Snippet

Sponsor: Emergent BioSolutions | Conditions: Smallpox Vaccine Adverse Reaction | Phase 3 | Status: COMPLETED | Results posted: 2019-03-26